Pfizer completes acquisition of Therachon
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key milestones in the development and commercialization of TA-46.
LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- Details
- Category: Bayer
LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition with the closing in the United States on September 4, 2018.
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio
- Details
- Category: Novartis
Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease[1].
Sanofi and Google to develop new healthcare Innovation Lab
- Details
- Category: Sanofi
Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies. The collaboration aims to change how Sanofi develops new treatments and will focus on three key objectives:
Bristol-Myers Squibb provides update on pending merger with Celgene
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: CELG). The Company remains actively engaged in discussions with the U.S. Federal Trade Commission ("FTC") on the FTC's continued review of the proposed transaction.
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
- Details
- Category: Bayer
Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer. This marks the start of an international, innovative study with a seamless Phase II/III design set up to rapidly identify effective therapies for patients with GBM;
Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease
- Details
- Category: AstraZeneca
AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD). This is the first global regulatory approval for Breztri Aerosphere and is the first approval by
More Pharma News ...
- Japan becomes the first country to approve Roche's personalised medicine Rozlytrek
- FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab)
- FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
- Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
- Nucala (mepolizumab) gains FDA approval for two new self-administration options
- Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development
- Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®